[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"1fa5498c-1aea-4d87-9474-f28a1ded3063","acronym":"MANTA","url":"https://clinicaltrials.gov/study/NCT02216786","created_at":"2021-01-18T10:23:25.940Z","updated_at":"2025-02-25T15:06:06.929Z","phase":"Phase 2","brief_title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","source_id_and_acronym":"NCT02216786 - MANTA","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 01/16/2014","start_date":" 01/16/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2024-12-02"},{"id":"5cc7ea58-5792-4936-b0c7-76d10e021a5b","acronym":"PASTOR","url":"https://clinicaltrials.gov/study/NCT02599714","created_at":"2021-01-18T12:37:17.664Z","updated_at":"2024-07-02T16:34:37.661Z","phase":"Phase 1","brief_title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","source_id_and_acronym":"NCT02599714 - PASTOR","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 03/30/2018","primary_completion_date":" 03/30/2018","study_txt":" Completion: 11/23/2023","study_completion_date":" 11/23/2023","last_update_posted":"2024-06-06"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"bf025afb-cb7b-4218-a07e-2e1a6a998168","acronym":"VICTORIA","url":"https://clinicaltrials.gov/study/NCT02730923","created_at":"2021-01-18T13:22:14.129Z","updated_at":"2024-07-02T16:35:19.665Z","phase":"Phase 1/2","brief_title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","source_id_and_acronym":"NCT02730923 - VICTORIA","lead_sponsor":"Centre Leon Berard","biomarkers":" ER • PGR • ABCB1","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR • ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-13"},{"id":"7b27da0a-d639-42fd-a136-368d479a1f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02831257","created_at":"2021-01-18T13:53:02.982Z","updated_at":"2025-02-25T15:07:09.140Z","phase":"Phase 2","brief_title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","source_id_and_acronym":"NCT02831257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-13"},{"id":"39901d4d-3dee-40b7-99f7-2afa8c1da147","acronym":"","url":"https://clinicaltrials.gov/study/NCT01884285","created_at":"2021-01-18T08:27:26.840Z","updated_at":"2024-07-02T16:36:44.639Z","phase":"Phase 1","brief_title":"AZD8186 First Time In Patient Ascending Dose Study","source_id_and_acronym":"NCT01884285","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR • PTEN • PIK3CB","pipe":" | ","alterations":" HER-2 negative • PIK3CB mutation","tags":["HER-2 • ER • PGR • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • AZD8186 • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 02/07/2020","study_completion_date":" 02/07/2020","last_update_posted":"2020-05-29"},{"id":"f036c2b2-da87-41ef-bd33-09e033f853e5","acronym":"TORCMEK","url":"https://clinicaltrials.gov/study/NCT02583542","created_at":"2021-01-18T12:31:58.659Z","updated_at":"2025-02-25T15:06:51.572Z","phase":"Phase 1/2","brief_title":"A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers","source_id_and_acronym":"NCT02583542 - TORCMEK","lead_sponsor":"Queen Mary University of London","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MET • NRAS • PTEN • STK11 • NF1 • FGFR • mTOR","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MET • NRAS • PTEN • STK11 • NF1 • FGFR • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Koselugo (selumetinib) • sirolimus • vistusertib (AZD2014)"],"overall_status":"Unknown status","enrollment":" Enrollment 118","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-02-25"},{"id":"e28db5d4-d40f-4ff7-bc8d-89c8927b5c1a","acronym":"CaNCaP02","url":"https://clinicaltrials.gov/study/NCT02064608","created_at":"2021-01-18T09:29:14.786Z","updated_at":"2025-02-25T15:05:53.348Z","phase":"Phase 1","brief_title":"Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer","source_id_and_acronym":"NCT02064608 - CaNCaP02","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" EIF4EBP1","pipe":"","alterations":" ","tags":["EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-07-17"},{"id":"e84dfcb8-ed06-48f2-a68d-dc1bf332000f","acronym":"RICTOR_SC","url":"https://clinicaltrials.gov/study/NCT03166904","created_at":"2021-01-18T15:36:45.375Z","updated_at":"2024-07-02T16:36:59.456Z","phase":"Phase 2","brief_title":"Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy","source_id_and_acronym":"NCT03166904 - RICTOR_SC","lead_sponsor":"Samsung Medical Center","biomarkers":" RICTOR","pipe":" | ","alterations":" RICTOR amplification","tags":["RICTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RICTOR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 07/31/2018","study_completion_date":" 07/31/2018","last_update_posted":"2019-05-20"}]